GSK and Amicus Therapeutics Revise Migalastat Agreement
GSK and Amicus Therapeutics revise Fabry agreement entered into in July 2012.
GlaxoSmithKline (GSK) and Amicus Therapeutics have revised their drug-development under which Amicus has obtained global rights to develop and commercialize the investigational pharmacological chaperone migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Under the terms of the revised agreement:
- Amicus will have sole rights to the global drug development, regulatory and commercial activities for the next-generation Fabry ERT (migalastat HCl co-formulated with ERT) as well as migalastat HCl monotherapy
- GSK will be eligible for future regulatory and commercial milestone payments, as well as royalty payments.
- GSK will further invest $3 million in Amicus through an equity investment in a concurrent private placement in public equity (PIPE) transaction
Source: GlaxoSmithKline
Recent Videos
Related Content
Texas' MD Anderson Cancer Center Creates New Cell Therapy Institute
November 11th 2024Article
With the launch of the Institute for Cell Therapy Discovery and Innovation, the MD Anderson Cancer Center will bring together expertise in developing cell therapies for cancer, autoimmune diseases, and infections.
